ISPOR - EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar

Full Text

EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar

Abstract

Authors

S. Keady N. Goyert-Stephens Q. Xin L. Morris M. Thomas G. Foxon

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now